For the quarter ending 2025-09-30, ONCO had $553,041 increase in cash & cash equivalents over the period. -$3,177,829 in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -8,783,702 | -10,918,327 |
| Amortization of debt discounts | 115,196 | 4,966 |
| Depreciation and amortization | 3,387 | 8,447 |
| Net periodic pension benefit | 246,080 | 107,304 |
| Stock-based compensation | 9,795 | 60,238 |
| Loss on extinguishment of notes payable | 5,384,719 | - |
| Loss on extinguishment of series c preferred stock | 196,244 | - |
| Loss on issuance of series d preferred stock | 2,543,329 | - |
| Change in fair value of contingent warrant liabilities | -36 | -10,024 |
| Change in fair value of warrant liabilities | -1,934,000 | - |
| Change in fair value of derivative liabilities | 216,000 | - |
| Change in fair value of subscription agreement liability related party | 0 | 3,127,962 |
| Gain on forgiveness of accounts payable | 0 | 944,694 |
| Loss on disposal of property and equipment | -551 | -16,482 |
| Accounts receivable | -9,559 | -15,685 |
| Inventories | 1,417 | 72,765 |
| Prepaid expenses and other current assets | -169,489 | -201,379 |
| Deferred offering costs | 150,000 | - |
| Accounts payable | -775,167 | -272,801 |
| Accrued expenses | -427,930 | -9,952 |
| Loss on impairment of goodwill | -12,000 | 11,512,000 |
| Impairment of entadfi assets | 0 | 0 |
| Amortization of debt discount - related party | 0 | 0 |
| Interest accrued on note payable | 0 | 0 |
| Interest accrued on note payable related party | 0 | 0 |
| Loss on impairment of inventory of entadfi | 0 | 0 |
| Deferred tax benefit | 0 | 0 |
| Prepaid expenses, long-term | 0 | 0 |
| Net cash used in operating activities | -3,177,829 | -3,409,976 |
| Proceeds from issuance of note payable | 400,000 | 475,000 |
| Principal payments of notes payable | 5,410,029 | 1,537,331 |
| Payment for redemption of series c preferred stock | 0 | 1,713,570 |
| Proceeds from issuance of series d preferred stock and warrants | 9,301,200 | - |
| Proceeds from sale of common stock | -21 | 6,391,655 |
| Cash in lieu of shares | 0 | 926 |
| Proceeds from issuance of note payable related party | 0 | 0 |
| Payment of financing costs | 0 | 0 |
| Proceeds from exercise of preferred investment options, net | 0 | - |
| Proceeds from exercise of stock options | 0 | 0 |
| Proceeds from exercise of warrants | 0 | - |
| Net cash provided by financing activities | 4,291,150 | 3,614,828 |
| Effect of exchange rate changes on cash | -560,280 | -567,837 |
| Purchases of property and equipment | 0 | 0 |
| Net cash provided by (used in) investing activities | 0 | 0 |
| Net increase (decrease) in cash | 553,041 | -362,985 |
| Cash and cash equivalents at beginning of period | 646,500 | - |
| Cash and cash equivalents at end of period | 836,556 | - |
Onconetix, Inc. (ONCO)
Onconetix, Inc. (ONCO)